Abstract Background: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A...
Read More
The work shows the problems faced by Iranian patients with congenital bleeding diseases following...
Damoctocog alfa pegol (Jivi®) is approved in the USA, EU, Japan and Canada for...
Prophylactic treatment regimens lead to improvements in health-related quality- of-life (HRQoL) among individuals with...
Patients on oral anticoagulant treatment and patients with severe bleeding diseases People being...
The International Society on Thrombosis and Haemostasis (ISTH) recommends that all eligible adults continue...
The SARS-CoV-2 coronavirus-induced infection (COVID-19) can be associated with a coagulopathy mainly responsible for...
Hepatitis E has emerged as a major transfusion-transmitted infectious risk. Two recipients of plasma...
BAY 94‐9027 (damoctocog alfa pegol; Jivi®; Bayer AG, Germany) is an extended half‐life B‐domain–deleted,...
It is important that hemophilia treatment centres, in close collaboration with patient organizations, take...